"Sarepta Stock Soars 38% After FDA Expands Gene Therapy Approval"
Peter Marks, a top FDA official, overruled staff and review teams to approve Sarepta Therapeutics' gene therapy Elevidys for nearly all Duchenne muscular dystrophy patients, despite the drug failing a Phase 3 trial and significant uncertainty about its benefits.